论文部分内容阅读
在防治食管静脉曲张破裂出血的多种方法中,通过前瞻性对比分析,治疗性或预防性门腔分流术不但不能提高生存率,反而能加速肝功衰竭和好发肝性脑病。因此,1939年 Crawfoord 首倡的食管静脉曲张的硬化剂注射疗法(Esophageal Varic-al Sclerotherapy:EVS),近年来重新受到各大医疗中心的普遍采用。为了确定 EVS 的地位,本文收集近三年来有关资料,作对比分析,以期客观地反映确切疗效。
In the prevention and treatment of esophageal variceal bleeding in a variety of methods, through prospective comparative analysis, curative or prophylactic gastrectomy can not only improve survival, but can accelerate liver failure and predominant hepatic encephalopathy. Therefore, esophageal varical-al Sclerotherapy (EVS), first introduced by Crawfoord in 1939, has been re-adopted by major medical centers in recent years. In order to determine the status of the EVS, this article collects the relevant information for the past three years for comparative analysis, with a view to objectively reflect the exact effect.